Showing results (391-400 of 494) with videos related to
Sort By:
Pageof 50
Annals of Surgical Oncology|June 14, 2013
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experiencePiotr Rutkowski, Alessandro Gronchi, Peter Hohenberger, et al.JAMA Surgery|April 3, 2020
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on SarcomasPaolo G Casali, Axel Le Cesne, Andres Poveda Velasco, et al.Annals of Surgery|July 14, 2022
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) ResultsDario Callegaro, Chandrajit P Raut, Taiwo Ajayi, et al.European Journal of Cancer (Oxford, England : 1990)|April 25, 2023
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective AnalysisJuergen Hench, Daniela Mihic-Probst, Abbas Agaimy, et al.The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.European Journal of Cancer (Oxford, England : 1990)|April 8, 2025
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 studyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.Lancet (London, England)|November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.The New England Journal of Medicine|November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinibCaroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Georgina V Long, Caroline Robert, et al.Pageof 50